Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99


Any time

2019 ( 10 )

2018 ( 4 )

2017 ( 5 )

2016 ( 8 )

Custom range...

Search Results: 1 - 10 of 3476 matches for " Federico Monzon "
All listed articles are free for downloading (OA Articles)
Page 1 /3476
Display every page Item
Identification of tissue of origin in carcinoma of unknown primary with a microarray-based gene expression test
Federico A Monzon, Fabiola Medeiros, Maureen Lyons-Weiler, W David Henner
Diagnostic Pathology , 2010, DOI: 10.1186/1746-1596-5-3
Abstract: The Pathwork? TOO Test was used to measure gene expression patterns for 1550 genes; these were compared for similarity to patterns from 15 known tissue types.The TOO Test yielded a clear single positive call for the primary site in 16 of 21 (76%) specimens and was indeterminate in 5 (24%). The positive results were consistent with clinicopathologic suggestions in 10 of the 16 cases (62%). In the remaining six cases the positive results were considered plausible based on clinical information. Positive calls included colorectal (5), breast (4), ovarian (3), lung (2), and pancreas (2). The TOO Test ruled out an average of 11 primary tissues in each CUP specimen.The Pathwork TOO Test reduced diagnostic uncertainty in all CUP cases and could be a valuable addition or alternative to current diagnostic methods for classifying uncertain primary cancers.Patients with carcinoma of unknown primary (CUP) present with metastatic disease for which the tissue of origin (TOO) cannot be identified. About 3%-5% of all diagnosed cancers are classified as CUP [1-4] and an estimated 31,490 new cases of cancer of unspecified primary sites were diagnosed in the United States in 2008 [5]. Prognosis of patients with CUP is usually poor with empiric treatment. Median survival is 3-9 months even with newer combination regimens [4,6-10]. It has been shown that survival can improve if the primary site is identified and specific therapy is instituted [11,12] as currently recommended in therapeutic guidelines [4,13].Unfortunately, primary tumor detection remains challenging. While serum tumor markers, imaging tests, and immunohistochemistry (IHC) panels can help identify the tissue of origin, the primary site is identified in fewer than 30% of those who present initially with occult primary tumor [13-15]. Furthermore, some positive findings can be misleading [2,16]. For example, in three large IHC studies (>50 specimens) of known metastatic specimens, IHC findings failed to agree with the site of
Linear Phase Perfect Reconstruction Filters and Wavelets with Even Symmetry
Lucas Monzon
Mathematics , 2011,
Abstract: Perfect reconstruction filter banks can be used to generate a variety of wavelet bases. Using IIR linear phase filters one can obtain symmetry properties for the wavelet and scaling functions. In this paper we describe all possible IIR linear phase filters generating symmetric wavelets with any prescribed number of vanishing moments. In analogy with the well known FIR case, we construct and study a new family of wavelets obtained by considering maximal number of vanishing moments for each fixed order of the IIR filter. Explicit expressions for the coefficients of numerator, denominator, zeroes, and poles are presented. This new parameterization allows one to design linear phase quadrature mirror filters with many other properties of interest such as filters that have any preassigned set of zeroes in the stopband or that satisfy an almost interpolating property. Using Beylkin's approach, it is indicated how to implement these IIR filters not as recursive filters but as FIR filters.
Pattern-Selection Based Power Analysis and Discrimination of Low- and High-Grade Myelodysplastic Syndromes Study Using SNP Arrays
Xiaorong Yang, Xiaobo Zhou, Wan-Ting Huang, Lingyun Wu, Federico A. Monzon, Chung-Che Chang, Stephen T. C. Wong
PLOS ONE , 2009, DOI: 10.1371/journal.pone.0005054
Abstract: Copy Number Aberration (CNA) in myelodysplastic syndromes (MDS) study using single nucleotide polymorphism (SNP) arrays have been received increasingly attentions in the recent years. In the current study, a new Constraint Moving Average (CMA) algorithm is adopted to determine the regions of CNA regions first. In addition to large regions of CNA, using the proposed CMA algorithm, small regions of CNA can also be detected. Real-time Polymerase Chain Reaction (qPCR) results prove that the CMA algorithm presents an insightful discovery of both large and subtle regions. Based on the results of CMA, two independent applications are studied. The first one is power analysis for sample estimation. An accurate estimation of sample size needed for the desired purpose of an experiment will be important for effort-efficiency and cost-effectiveness. The power analysis is performed to determine the minimum sample size required for ensuring at least () detected regions statistically different from normal references. As expected, power increase with increasing sample size for a fixed significance level. The second application is the distinguishment of high-grade MDS patients from low-grade ones. We propose to calculate the General Variant Level (GVL) score to integrate the general information of each patient at genotype level, and use it as the unified measurement for the classification. Traditional MDS classifications usually refer to cell morphology and The International Prognostic Scoring System (IPSS), which belongs to the classification at the phenotype level. The proposed GVL score integrates the information of CNA region, the number of abnormal chromosomes and the total number of the altered SNPs at the genotype level. Statistical tests indicate that the high and low grade MDS patients can be well separated by GVL score, which appears to correlate better with clinical outcome than the traditional classification approaches using morphology and IPSS sore at the phenotype level.
Synchronous clear cell renal cell carcinoma and tubulocystic carcinoma: genetic evidence of independent ontogenesis and implications of chromosomal imbalances in tumor progression
Gabriela Quiroga-Garza, Sergio Pi?a-Oviedo, Karime Cuevas-Ocampo, Richard Goldfarb, Mary R Schwartz, Alberto G Ayala, Federico A Monzon
Diagnostic Pathology , 2012, DOI: 10.1186/1746-1596-7-21
Abstract: The virtual slide(s) for this article can be found here:http://www.diagnosticpathology.diagnomx.eu/vs/1790525735655283 webciteKidney cancer is among the ten most common causes of cancer-related death in adults [1]. Over 64,700 new cases and over 13,500 deaths are expected to occur in the US in 2012 [2]. Renal cell carcinoma (RCC) constitutes more than 80% of all primary renal neoplasms, and clear cell RCC (ccRCC) accounts for most of these cases (80%). While a specific histological diagnosis is possible by morphology and immunohistochemistry in the majority of cases, overlapping morphological features are still encountered in about 7% of cases in routine practice [3], and these cases fall in the category of "unclassified renal neoplasm." Recent updates to the histopathological diagnosis of kidney neoplasms are reflected in the latest World Health Organization (WHO) classification of genitourinary and kidney neoplasms [4]. However, ongoing research has led to the description of new tumor entities that are not yet considered in this classification. One of these recently described entities is tubulocystic renal carcinoma (TCRC) with less than one hundred cases reported [5].Genetic events play an important role in renal carcinogenesis, and most known renal tumor subtypes have recurrent specific chromosomal imbalances [6]. Thus, genetic profiling of renal tumors has emerged as a practical diagnostic tool for the surgical pathologist, especially in those cases where morphologic diagnosis is not conclusive [3]. Although the identification of key molecular targets involved in renal carcinogenesis has had direct impact in patient care, little is known about the genetic events involved in tumor progression [6].Herein we describe the clinico-pathological features of a patient presenting with synchronous ccRCC and a TCRC and the molecular profiles of these tumors utilizing virtual karyotyping. Our results contrast the different profiles of these tumors as well as exemplify the
Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process
Uma R Chandran, Changqing Ma, Rajiv Dhir, Michelle Bisceglia, Maureen Lyons-Weiler, Wenjing Liang, George Michalopoulos, Michael Becich, Federico A Monzon
BMC Cancer , 2007, DOI: 10.1186/1471-2407-7-64
Abstract: Using Affymetrix oligonucleotide arrays, we analyzed gene expression profiles of 24 androgen-ablation resistant metastatic samples obtained from 4 patients and a previously published dataset of 64 primary prostate tumor samples. Differential gene expression was analyzed after removing potentially uninformative stromal genes, addressing the differences in cellular content between primary and metastatic tumors.The metastatic samples are highly heterogenous in expression; however, differential expression analysis shows that 415 genes are upregulated and 364 genes are downregulated at least 2 fold in every patient with metastasis. The expression profile of metastatic samples reveals changes in expression of a unique set of genes representing both the androgen ablation related pathways and other metastasis related gene networks such as cell adhesion, bone remodelling and cell cycle. The differentially expressed genes include metabolic enzymes, transcription factors such as Forkhead Box M1 (FoxM1) and cell adhesion molecules such as Osteopontin (SPP1).We hypothesize that these genes have a role in the biology of metastatic disease and that they represent potential therapeutic targets for prostate cancer.Prostate cancer is the most common cancer in men resulting in over 232,090 new cases and 30,350 deaths annually [1]. For prostate cancer patients, metastatic disease reflects the most adverse clinical outcome. Osseous involvement with severe bone pain and spinal cord complications occur commonly in patients with metastatic disease [2]. However there is considerable heterogeneity in outcome after primary diagnosis and currently there are no morphologic or circulating biomarkers that can accurately predict the development of metastatic disease.Metastatic prostate cancer represents the tumor's ability to escape from the primary organ and eventually colonize a distant site. Disruption of a complex set of biological processes must occur in order for tumor cells to leave the pro
Targeted agents for the treatment of metastatic melanoma
Monzon JG, Dancey J
OncoTargets and Therapy , 2012, DOI: http://dx.doi.org/10.2147/OTT.S21259
Abstract: rgeted agents for the treatment of metastatic melanoma Review (3604) Total Article Views Authors: Monzon JG, Dancey J Published Date March 2012 Volume 2012:5 Pages 31 - 46 DOI: http://dx.doi.org/10.2147/OTT.S21259 Received: 29 November 2011 Accepted: 15 January 2012 Published: 05 March 2012 Jose G Monzon, Janet Dancey NCIC Clinical Trials Group, Kingston, Ontario, Canada Abstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.
Targeted agents for the treatment of metastatic melanoma
Monzon JG,Dancey J
OncoTargets and Therapy , 2012,
Abstract: Jose G Monzon, Janet DanceyNCIC Clinical Trials Group, Kingston, Ontario, CanadaAbstract: In the last year, the armamentarium of melanoma therapeutics has radically changed. Recent discoveries in melanoma biology and immunology have led to novel therapeutics targeting known oncogenes and immunotherapeutic antibodies. Phase III clinical trials of these agents have reported measurable and meaningful benefits to patients with metastatic disease. In this article, we review recent findings and discuss their significance in melanoma therapy. As our understanding of melanoma biology grows, this initial therapeutic success may be enhanced through the use of molecular markers to select patients, and new targeted immunotherapies in sequential or combination drug regimens.Keywords: metastatic melanoma, ipilimumab, vemurafenib, antitumor
Having a Heart for ALL Students
Dawn M. Monzon
Christian Perspectives in Education , 2009,
Abstract: The student body in today’s general educational classrooms continues to increase in diversity, with many of the students being English language learners. This growth in the number of non-English speaking students brings challenges to educators. Students’ test scores are the measurement of success for educators, resulting in a decrease of caring about students as individuals. This article addresses the importance and responsibility for Christian educators to reach out to non-English speaking students
The minimal angle condition for quadrilateral finite elements of arbitrary degree
Acosta Gabriel,Monzon Gabriel
Mathematics , 2015,
Abstract: We study $W^{1,p}$ Lagrange interpolation error estimates for general quadrilateral $\mathcal{Q}_{k}$ finite elements with $k\ge 2$. For the most standard case of $p=2$ it turns out that the constant $C$ involved in the error estimate can be bounded in terms of the minimal interior angle of the quadrilateral. Moreover, the same holds for any $p$ in the range $1\le p<3$. On the other hand, for $3\le p$ we show that $C$ also depends on the maximal interior angle. We provide some counterexamples showing that our results are sharp.
Virtual karyotyping with SNP microarrays reduces uncertainty in the diagnosis of renal epithelial tumors
Jill M Hagenkord, Anil V Parwani, Maureen A Lyons-Weiler, Karla Alvarez, Robert Amato, Zoran Gatalica, Jose M Gonzalez-Berjon, Leif Peterson, Rajiv Dhir, Federico A Monzon
Diagnostic Pathology , 2008, DOI: 10.1186/1746-1596-3-44
Abstract: To investigate the use of virtual karyotypes for diagnostically challenging renal epithelial tumors, we evaluated 25 archived renal neoplasms where sub-classification could not be definitively rendered based on morphology and other ancillary studies. We generated virtual karyotypes with the Affymetrix 10 K 2.0 mapping array platform and identified the presence of genomic lesions across all 22 autosomes.In 91% of challenging cases the virtual karyotype unambiguously detected the presence or absence of chromosomal aberrations characteristic of one of the common subtypes of renal epithelial tumors, while immunohistochemistry and fluorescent in situ hybridization had no or limited utility in the diagnosis of these tumors.These results show that virtual karyotypes generated by SNP arrays can be used as a practical ancillary study for the classification of renal epithelial tumors with complex or ambiguous morphology.Each year in the United States, there are approximately 31,900 cases of kidney and upper urinary tract cancer that account for approximately 3% of adult malignancies, and result in more than 11,900 deaths [1]. The most common types of renal epithelial tumors are clear cell renal cell carcinoma (RCC) (75%), papillary RCC (10%), chromophobe RCC (5%), and benign oncocytoma (5%)[2]. Correct pathological classification is critical for prognosis, management, therapy, and eligibility for clinical trials. Classification of renal epithelial tumors is primarily based on cytologic appearance, cell type of origin, and growth pattern. Morphological distinction among the renal cell tumor subtypes is generally straightforward after routine pathologic examination of the tissue. However, a subset of cases are ultimately diagnosed as renal cell carcinoma, unclassified, due to the presence of non-specific features that can be seen in all of the subtypes (such as granular, oncocytic or sarcomatoid morphology) [3] or the presence of more than one subtype in the same tumor [2].Spec
Page 1 /3476
Display every page Item

Copyright © 2008-2017 Open Access Library. All rights reserved.